PuSH - Publication Server of Helmholtz Zentrum München

Journal browsing

28 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
Dawed, A.Y.* et al.: Pharmacogenomics of GLP-1 receptor agonists: A genome-wide analysis of observational data and large randomised controlled trials. Lancet Diabet. Endocrinol. 11, 33-41 (2023)
Bechmann, N.* et al.: Sexual dimorphism in COVID-19: Potential clinical and public health implications. Lancet Diabet. Endocrinol. 10, 221-230 (2022)
Ghalwash, M.* et al.: Two-age islet-autoantibody screening for childhood type 1 diabetes: A prospective cohort study. Lancet Diabet. Endocrinol. 10, 589-596 (2022)
Stefan, N. & Cusi, K.*: A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabet. Endocrinol. 10, 284-296 (2022)
Steenblock, C.* et al.: COVID-19 and metabolic disease: Mechanisms and clinical management. Lancet Diabet. Endocrinol. 9, 786-798 (2021)
Bornstein, S.R. et al.: Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabet. Endocrinol. 8, 546-550 (2020)
Kullmann, S. et al.: Central nervous pathways of insulin action in the control of metabolism and food intake. Lancet Diabet. Endocrinol. 8, 524-534 (2020)
Kurz, C.F. & König, A.: The causal influence of maternal obesity on preterm birth. Lancet Diabet. Endocrinol. 8, 101-103 (2020)
Rubino, F.* et al.: Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. Lancet Diabet. Endocrinol. 8, 640-648 (2020)
Rubino, F. ; Zimmet, P.* & Ludwig, B.: Management of diabetes in patients with COVID-19 – Authors' reply. Lancet Diabet. Endocrinol. 8, 669-670 (2020)
Stefan, N.: Causes, consequences, and treatment of metabolically unhealthy fat distribution. Lancet Diabet. Endocrinol. 8, 616-627 (2020)
Tofte, N.* et al.: Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): A prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabet. Endocrinol. 8, 301-312 (2020)
Turcu, A.F.* & Walch, A.K.: A multi-test strategy for adrenal tumours. Lancet Diabet. Endocrinol. 8, 733-734 (2020)
Stefan, N. ; Häring, H.-U. & Cusi, K.*: Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabet. Endocrinol. 7, 313-324 (2019)
Zaharia, O.P.* et al.: Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: A 5-year follow-up study. Lancet Diabet. Endocrinol. 7, 684-694 (2019)
Eckel, N.* et al.: Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses' Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabet. Endocrinol. 6, 714-724 (2018)
Dandona, P.* et al.: Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabet. Endocrinol. 5, 864-876 (2017)
Stefan, N. ; Häring, H.-U. & Schulze, M.B.*: Metabolically healthy obesity: The low-hanging fruit in obesity treatment? Lancet Diabet. Endocrinol. 6, 249-258 (2017)
EUMODIC Consortium (Peters, A. ; Heid, I.): Natriuretic peptides and integrated risk assessment for cardiovascular disease: An individual-participant-data meta-analysis. Lancet Diabet. Endocrinol. 4, 840-849 (2016)
Stefan, N. ; Häring, H.-U. ; Hu, F.B.* & Schulze, M.B.*: Divergent associations of height with cardiometabolic disease and cancer: Epidemiology, pathophysiology, and global implications. Lancet Diabet. Endocrinol. 4, 457-467 (2016)